Monitoring and assessing vaccine safety: a European perspective
- PMID: 20370548
- DOI: 10.1586/erv.10.20
Monitoring and assessing vaccine safety: a European perspective
Abstract
The success of vaccination programs is an uncontroversial reality--in Europe as well as worldwide. On the other hand, the perceived risk of adverse events in the general public is the most important threat for implementing successful vaccination programs in Europe. For this reason, monitoring and assessing vaccine safety is a priority for public health. Vaccine safety is assessed both before and after vaccine authorization. In postmarketing settings, different activities related to vaccine safety usually involve several different stakeholders. In 2005, a new EU agency, the European Centre for Disease Prevention and Control, was established with the aim to strengthen Europe's defences against infectious diseases. Implementing stable links between different stakeholders and defining clear roles in the EU is paramount in order to provide optimal and transparent information on adverse reactions following immunization, with the final goal of increasing compliance to safe and effective vaccination programs.
Similar articles
-
Vaccinovigilance in Europe--need for timeliness, standardization and resources.Bull World Health Organ. 2004 Nov;82(11):828-35. Epub 2004 Dec 14. Bull World Health Organ. 2004. PMID: 15640918 Free PMC article.
-
The Vaccine Safety Datalink: a model for monitoring immunization safety.Pediatrics. 2011 May;127 Suppl 1:S45-53. doi: 10.1542/peds.2010-1722H. Epub 2011 Apr 18. Pediatrics. 2011. PMID: 21502240 Review.
-
Understanding the role of human variation in vaccine adverse events: the Clinical Immunization Safety Assessment Network.Pediatrics. 2011 May;127 Suppl 1:S65-73. doi: 10.1542/peds.2010-1722J. Epub 2011 Apr 18. Pediatrics. 2011. PMID: 21502239
-
[Essential to monitor vaccine safety].Lakartidningen. 2001 Sep 5;98(36):3777-8. Lakartidningen. 2001. PMID: 11586806 Swedish.
-
Global safety of vaccines: strengthening systems for monitoring, management and the role of GACVS.Expert Rev Vaccines. 2009 Jun;8(6):705-16. doi: 10.1586/erv.09.40. Expert Rev Vaccines. 2009. PMID: 19485752 Review.
Cited by
-
Adverse Events Following Measles-Mumps-Rubella-Varicella Vaccination and the Case of Seizures: A Post Marketing Active Surveillance in Puglia Italian Region, 2017-2018.Vaccines (Basel). 2019 Oct 7;7(4):140. doi: 10.3390/vaccines7040140. Vaccines (Basel). 2019. PMID: 31591347 Free PMC article.
-
Vaccine safety: An evolving evidence-based science.Br J Clin Pharmacol. 2019 Dec;85(12):2649-2651. doi: 10.1111/bcp.14080. Epub 2019 Aug 19. Br J Clin Pharmacol. 2019. PMID: 31373717 Free PMC article. No abstract available.
-
Vaccine Adjuvants: from 1920 to 2015 and Beyond.Vaccines (Basel). 2015 Apr 16;3(2):320-43. doi: 10.3390/vaccines3020320. Vaccines (Basel). 2015. PMID: 26343190 Free PMC article. Review.
-
Near real-time vaccine safety surveillance using electronic health records-a systematic review of the application of statistical methods.Pharmacoepidemiol Drug Saf. 2016 Mar;25(3):225-37. doi: 10.1002/pds.3966. Epub 2016 Jan 28. Pharmacoepidemiol Drug Saf. 2016. PMID: 26817940 Free PMC article.
-
The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety.Vaccine. 2014 Sep 22;32(42):5390-8. doi: 10.1016/j.vaccine.2014.07.073. Epub 2014 Aug 6. Vaccine. 2014. PMID: 25108215 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical